NCT03695250 - BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 16, 2018

Primary Completion Date

November 24, 2020

Study Completion Date

March 12, 2021

Conditions

Metastatic Hepatocellular CarcinomaStage III Hepatocellular Carcinoma AJCC v8Stage IIIA Hepatocellular Carcinoma AJCC v8Stage IIIB Hepatocellular Carcinoma AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8Stage IVA Hepatocellular Carcinoma AJCC v8Stage IVB Hepatocellular Carcinoma AJCC v8Unresectable Hepatocellular Carcinoma

Interventions

DRUG

IDO1 Inhibitor BMS-986205

Given PO

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (1)

95817

University of California Davis Comprehensive Cancer Center, Sacramento